Implantable insulin pumps are emerging insulin-delivery devices that can be surgically implanted under the skin of individuals with diabetes. The pump delivers a continuous basal dose of insulin through a catheter and into the patient’s abdominal cavity. Patients can self-administer a bolus dose with a remote-control device.

These pumps are still used only experimentally in the United States but are available overseas. Initial trials have been encouraging, with patients appearing to experience fewer episodes of hypoglycemia. However, occasional complications have emerged, including blockage of the catheter and infection or other skin conditions at the implantation site.

Eventually, it is hoped that technology will allow implantable insulin pumps to progress to the level of an artificial pancreas. Such a device would not only deliver insulin but also monitor glucose (blood sugar) to determine how much insulin to secrete at a given moment.